Moderna Q4 2023 revenue $2.8B, EPS $0.55; FY net loss $4.7B from $3.7B non-cash charges

Moderna, Inc.

2023-FY EPS reported -$12.33 revenue$6,848,000,000

Q4 revenue $2.8B (-43% YoY); GAAP net income $217M, diluted EPS $0.55.
FY2023 revenue $6.8B; GAAP net loss $4.7B, diluted EPS ($12.33) from $3.7B non-cash charges (resizing, valuation allowance).
Reaffirms 2024 product sales ~$4B; expects RSV vaccine (mRNA-1345) regulatory approvals beginning H1 2024 (PDUFA May 12).
FY2023 COVID vaccine sales $6.7B; U.S. retail market share 48% (vs 37% in 2022).
2024 guidance: cost of sales ~35% of product sales; R&D ~$4.5B; SG&A ~$1.3B; year-end cash ~$9B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moderna, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $2.8 billion, net income $217 million, EPS $0.55. Guidance reaffirmed.

Period: the fourth quarter and year ended December 31, 2023
Revenue: $2.8 billion
Net income: $217 million
EPS: $0.55
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55

View on SEC.gov

Browse all earnings releases →

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.